Replies to post #195851 on Biotech Values

[biomaven0]

I as considering using the EXAS test instead of a colonoscopy, but I now note it's not covered by Blue Cross Blue Shield in Massachusetts.

If they were smart they would figure out someway to cap the out-of-pocket costs - better to make a sale (even at breakeven or a small loss) than lose it altogether.

[DewDiligence]

EXAS 2.5-year low—down 77%(!) from Jun 2015 high.

[DewDiligence]

EXAS -13% on soft 4Q15/unchanged 2016 guidance:

http://finance.yahoo.com/news/exact-sciences-announces-preliminary-fourth-110000111.html

Based on Exact Sciences' current forecasts, the company is reaffirming its guidance of completing more than 240,000 Cologuard tests and generating between $90-100 million in revenue in 2016. This represents a greater than 130-percent year-over-year increase in the number of Cologuard tests completed.

Some investors apparently expected EXAS to raise 2016 guidance.

The share price is down 79%(!) from its Jun 2015 high.